1
|
Price GL, Sudharshan L, Ryan P, Rajkumar J, Sheffield KM, Nash Smyth E, Morato Guimaraes C, Rybowski S, Cuyun Carter G, Gathirua-Mwangi WG, Huang YJ. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. Curr Med Res Opin 2022; 38:1319-1331. [PMID: 35535675 DOI: 10.1080/03007995.2022.2073122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To examine the real-world incidence and management of select adverse events (AEs) among female patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), receiving a cyclin-dependent kinase 4 and 6 (CDK4 and 6) inhibitor (palbociclib, abemaciclib, or ribociclib). METHODS This retrospective study analyzed data from the US Oncology Network iKnowMed electronic health record database for 396 patients with an initial MBC diagnosis on/after 1 January 2014 and receipt of first CDK4 and 6 regimen between 1 January 2017 and 31 December 2018. In this descriptive study, the proportion of patients who experienced select AEs and associated dose modifications or discontinuations were reported. The occurrence of select healthcare resource utilization categories was also reported. RESULTS Median follow-up time was 451, 262, and 355 days for patients in the palbociclib, abemaciclib, and ribociclib cohorts, respectively. The most common AEs were neutropenia (palbociclib, 44.8%; abemaciclib, 10.6%; ribociclib, 36.3%), diarrhea (palbociclib, 8.0%; abemaciclib, 43.0%; ribociclib, 8.8%), and fatigue (palbociclib, 12.9%; abemaciclib, 17.6%; ribociclib, 16.5%). AEs resulted in a treatment hold among 91 (23.0%), a dose reduction among 86 (21.7%), and permanent discontinuation among 48 (12.1%) patients overall. CONCLUSIONS This real-world study provides insight into the occurrence of AEs which varied by CDK4 and 6 inhibitor. Compared to clinical trials, frequencies of AEs were numerically lower but dose reductions due to AEs were numerically higher. It is possible these differences reflect proactive management of AEs on the part of clinicians to help patients remain on therapy.
Collapse
Affiliation(s)
| | | | - Paula Ryan
- Texas Oncology - The Woodlands, The Woodlands, TX, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Price GL, Cinfio FN, Martin PA, Vitko AS, Boye ME, DeLuca A, Bly CA, Manion C, Brown J. HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%. J Natl Compr Canc Netw 2022. [DOI: 10.6004/jnccn.2021.7222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Gregory L Price
- 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
| | - Frank N Cinfio
- 2 Medical Decision Modeling (MDM) Inc., Indianapolis, IN
| | | | | | - Mark E Boye
- 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
| | - Angelo DeLuca
- 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
| | | | - Chelsea Manion
- 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
| | - Jacqueline Brown
- 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
| |
Collapse
|
3
|
Tolaney SM, Beeram M, Beck JT, Conlin A, Dees EC, Puhalla SL, Rexer BN, Burris HA, Jhaveri K, Helsten T, Becerra C, Kalinsky K, Moore KN, Manuel AM, Lithio A, Price GL, Chapman SC, Litchfield LM, Goetz MP. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Front Oncol 2022; 11:810023. [PMID: 35223458 PMCID: PMC8868006 DOI: 10.3389/fonc.2021.810023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 12/20/2021] [Indexed: 11/29/2022] Open
Abstract
Background Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhibitor or fulvestrant in patients with advanced or metastatic breast cancer. This Phase 1b study evaluated the safety and tolerability, pharmacokinetics, and antitumor activity of abemaciclib in combination with endocrine therapy for metastatic breast cancer (MBC), including aromatase inhibitors (letrozole, anastrozole, or exemestane) or tamoxifen. Patients and Methods Women ≥18 years old with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) MBC were eligible for enrollment. Eligibility included measurable disease or non-measurable but evaluable bone disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, Eastern Cooperative Oncology Group performance status 0–1, and no prior chemotherapy for metastatic disease. Adverse events were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 and tumor response were assessed by RECIST v1.1. Results Sixty-seven patients were enrolled and received abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20), anastrozole (Part B, n=16), tamoxifen (Part C, n=16), or exemestane (Part D, n=15). The most common treatment-emergent adverse events (TEAE) were diarrhea, fatigue, nausea, and abdominal pain. Grade 4 TEAEs were reported in five patients (one each with hyperglycemia, hypertension, neutropenia, procedural hemorrhage, and sepsis). There was no effect of abemaciclib or endocrine therapy on the pharmacokinetics of any combination study drug. Across all treated patients, the median progression-free survival was 25.4 months (95% confidence interval: 18.0, 35.8). The objective response rate was 38.9% in 36 patients with measurable disease. Conclusions Abemaciclib in combination with multiple endocrine therapy options exhibited manageable safety and promising antitumor activity in patients with HR+, HER2- MBC. Clinical Trial Registration https://clinicaltrials.gov/, identifier NCT02057133
Collapse
Affiliation(s)
- Sara M Tolaney
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
| | - Muralidhar Beeram
- South Texas Accelerated Research Therapeutics, San Antonio, TX, United States
| | - J Thaddeus Beck
- Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, United States
| | - Alison Conlin
- Providence Cancer Center, Portland, OR, United States
| | - E Claire Dees
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Shannon L Puhalla
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States
| | - Brent N Rexer
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Howard A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States
| | - Komal Jhaveri
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.,Department of Medicine, Weil Cornell Medical College, New York, NY, United States
| | - Teresa Helsten
- Moores Cancer Center, University of California San Diego, San Diego, CA, United States
| | | | - Kevin Kalinsky
- Department of Medicine, Columbia University, New York, NY, United States.,Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States
| | - Kathleen N Moore
- Stevenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.,Sarah Cannon Research Institute, Nashville, TN, United States
| | | | - Andrew Lithio
- Eli Lilly and Company, Indianapolis, IN, United States
| | | | | | | | - Matthew P Goetz
- Department of Oncology, Mayo Clinic, Rochester, MN, United States.,Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States
| |
Collapse
|
4
|
Vidal GA, Carter GC, Gilligan AM, Saverno K, Zhu YE, Price GL, DeLuca A, Smyth EN, Rybowski S, Huang YJ, Schwartzberg LS. Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting. Clin Breast Cancer 2021; 21:317-328.e7. [DOI: 10.1016/j.clbc.2020.12.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 12/03/2020] [Accepted: 12/28/2020] [Indexed: 02/02/2023]
|
5
|
Huang YJ, Ryan PD, Price GL, Carter GC, Sheffield KM, Smyth EN, Guimaraes CM, Rybowski S, Rajkumar J, Sudharshan L. HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting. J Natl Compr Canc Netw 2021. [DOI: 10.6004/jnccn.2020.7739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Stephenson JJ, Gable JC, Zincavage R, Price GL, Churchill C, Zhu E, Stenger K, Singhal M, Nepal B, Grabner M, Fisch MJ, Debono D, Geschwender AR, Cuyun Carter G. Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study. Patient Prefer Adherence 2021; 15:2417-2429. [PMID: 34764640 PMCID: PMC8573215 DOI: 10.2147/ppa.s319239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 10/19/2021] [Indexed: 12/26/2022] Open
Abstract
PURPOSE To describe patients' perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i's) to treat metastatic breast cancer (MBC). METHODS This qualitative study consisted of 60-minute semi-structured telephone interviews with patients with MBC in the US who were either current or recent CDK4&6i users, identified from administrative claims of survey-eligible commercial and Medicare Advantage patients in the HealthCore Integrated Research Database between November 1, 2018 and November 1, 2019. Patients were recruited by email and/or mailed letter. The 60-minute telephone interviews were conducted by a trained facilitator using a study-developed interview discussion guide that included topics impacting treatment choice and adherence/persistence. Interviews were audio-recorded, transcribed, and thematically analyzed. RESULTS All 462 eligible patients were sent a recruitment email and/or letter to which 36 patients responded, consented to participate, and met study inclusion criteria; 25 patients scheduled interviews, and 24 completed them. Study participants were predominately white, non-Hispanic (96%) with a mean age of 59.5 years. Participants reported a largely positive experience and mentioned very few adherence/persistence issues. They further reported appreciating the ease and convenience of oral oncolytics, coped with side effects, had strong medical and social support, and experienced few cost issues. CONCLUSION The few adherence/persistence issues reported by participants contrasts with other findings of suboptimal oral oncolytic use. Interview themes indicated several factors that likely contributed to the lack of adherence/persistence issues: trusted relationship with oncologist, belief in importance of medication, positive medication views, strong medical and social support, and minimal personal drug cost. Future research should focus on whether and how much these factors impact adherence/persistence in more diverse populations. If adherence/persistence issues are identified in these populations, then it would be appropriate to study the development of interventions that target factors associated with better adherence/persistence.
Collapse
Affiliation(s)
- Judith J Stephenson
- HealthCore, Inc., Wilmington, DE, USA
- Correspondence: Judith J Stephenson Tel +1 302-547-5770 Email
| | | | | | | | | | - Emily Zhu
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | - Bal Nepal
- HealthCore, Inc., Wilmington, DE, USA
| | | | | | | | | | | |
Collapse
|
7
|
Davie A, Carter GC, Rider A, Pike J, Lewis K, Bailey A, Price GL, Ringeisen F, Pivot X. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries. BMC Cancer 2020; 20:855. [PMID: 32894087 PMCID: PMC7487722 DOI: 10.1186/s12885-020-07294-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 08/11/2020] [Indexed: 12/24/2022] Open
Abstract
Background Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient symptoms and health-related quality of life (HRQoL) at the start of this changing therapeutic landscape. This real-world study describes the patient-reported outcomes (PROs) of women with HR+/HER2− advanced breast cancer receiving ET-based regimens who were naïve to systemic treatment in the advanced setting across five European countries (EU5). Methods Data were collected between March and July 2017 from surveyed oncologists and their patients at a single time point using the multinational Adelphi Advanced Breast Cancer Disease Specific Programme™. Patients completed PRO questionnaires on HRQoL (EORTC QLQ-C30), pain severity and interference, and work and activity impairment. A multiple linear regression model explored factors associated with HRQoL. Results Across EU5, 226 physicians provided data on 781 women with HR+/HER2− advanced breast cancer taking their first ET-based regimen for advanced disease, of whom 252 provided PRO data. This subset had a mean age of 67.1 years, 94% were postmenopausal, 89% were diagnosed with advanced breast cancer at initial presentation, 79% had stage IV disease (66% of these patients had bone metastases and 38% had visceral metastases, including 18% with liver metastases) and 77% were on endocrine-only therapy as their initial treatment for advanced disease. The mean EORTC QLQ-C30 global health score (50.9) was worse than the reference value for patients with advanced breast cancer (60.2). Fatigue, pain, and insomnia were the most severe symptoms, and mean functioning scores were also worse than reference values. “Worst pain” and “pain interference” were moderate/severe for 42 and 80% of patients. Mean activity impairment was 44%, and greater activity impairment was associated with poorer HRQoL. Conclusions Despite receiving first-line ET-based regimens for advanced disease, these women had a poor HRQoL and high levels of symptoms, pain, pain interference and activity impairment. New treatments that maintain a stable disease state and reduce activity impairment may have a positive effect on the HRQoL of those living with advanced breast cancer.
Collapse
Affiliation(s)
- Alison Davie
- Eli Lilly and Co Ltd, Windlesham, Surrey, GU20 6PH, UK.
| | | | - Alex Rider
- Adelphi Real World, Bollington, Macclesfield, Cheshire, SK10 5JB, UK
| | - James Pike
- Adelphi Real World, Bollington, Macclesfield, Cheshire, SK10 5JB, UK
| | - Katie Lewis
- Adelphi Real World, Bollington, Macclesfield, Cheshire, SK10 5JB, UK
| | - Abigail Bailey
- Adelphi Real World, Bollington, Macclesfield, Cheshire, SK10 5JB, UK
| | | | | | | |
Collapse
|
8
|
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020; 25:e1346-e1354. [PMID: 32536013 PMCID: PMC7485333 DOI: 10.1634/theoncologist.2020-0084] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Accepted: 05/21/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND MONARCH 3, a phase III trial (NCT02246621) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), previously demonstrated significantly improved progression-free survival in patients receiving abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI). This study evaluated patient-reported outcomes, including global health-related quality of life (HRQoL), functioning, and symptoms. METHODS Patients were randomly assigned 2:1 to receive abemaciclib (150 mg twice daily; n = 328) or placebo (n = 165), plus 1 mg anastrozole or 2.5 mg letrozole daily. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Breast Cancer-Specific Quality of Life Questionnaire HRQoL instruments were administered at baseline, every two cycles during cycles 2 through 19 (each cycle being 28 days), every three cycles thereafter, and once at a short-term posttherapy follow-up visit (approximately 30 days after discontinuation). Longitudinal mixed regression and Cox proportional hazards models evaluated postbaseline change and time to sustained deterioration (TTSD), respectively. RESULTS Baseline scores were similar between treatment arms. Although select scores statistically favored the placebo arm, global HRQoL, most symptoms, and functioning scales did not meet the threshold for clinically meaningful differences between treatment arms. Only diarrhea favored the placebo arm with statistically and clinically meaningful differences. There were no TTSD differences between treatment arms for global HRQoL, most symptoms (except diarrhea), or functioning. CONCLUSION Over a 2-year period, there were no clinically meaningful differences in global HRQoL, functioning, and most symptoms for patients receiving abemaciclib plus NSAI compared with NSAI alone. Only diarrhea favored the placebo arm, consistent with prior safety data, which has been shown to be manageable and reversible. Combined with clinical efficacy, results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC. IMPLICATIONS FOR PRACTICE The addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) was not associated with a clinically meaningful detriment in patient-reported global health-related quality of life, functioning, and most symptoms in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Prior studies have also demonstrated clinical efficacy of abemaciclib plus NSAI compared with NSAI alone, including improved progression-free survival and objective response rate. These results also complement previously reported toxicity data, as measured by investigator-assessed adverse events. Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC.
Collapse
Affiliation(s)
| | - Miguel Martin
- Instituto de Investigacion Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad ComplutenseMadridSpain
| | - Eriko Tokunaga
- National Hospital Organization, Kyushu Cancer CenterFukuokaJapan
| | - In Hae Park
- National Cancer CenterGyeonggi‐DoRepublic of South Korea
| | - Jens Huober
- Breast Center, Universitätsklinikum UlmUlmGermany
| | - Masakazu Toi
- Department of Surgery, Graduate School of Medicine, Kyoto UniversityKyotoJapan
| | | | | | | | | | | | | |
Collapse
|
9
|
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res 2020; 21:699-710. [PMID: 32755262 DOI: 10.1080/14737167.2020.1804871] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND Real-world evidence specific to HR+/HER2- metastatic breast cancer (MBC) prior to introduction of CDK4/6 inhibitors is limited. In an effort to provide context for the introduction of new treatments, we assessed treatment patterns, adverse events, productivity loss, and direct/indirect economic burden in a privately insured population of patients with HR+/HER2- MBC. RESEARCH DESIGN AND METHODS Using a retrospective cohort design, patients aged 18-64 years, selected from MarketScan databases (2007-2014), were analyzed using descriptive and multivariable methods. RESULTS Among 5,563 eligible patients, endocrine therapy was the most common first-line (1L) therapy; its utilization trended downward from 63% (1L) to 23% (4L), with a simultaneous increase in chemotherapy use, 25% (1L) to 50% (4L). Two hundred and seventy-eight unique treatment regimens were used in the 1L setting. The average per patient monthly all-cause costs were $14,424. The 12-month indirect costs for short-term disability were substantially higher in MBC patients ($10,397) than in matched noncancer patients ($394). CONCLUSION The increasing use of chemotherapy as patients progressed to second and later lines and the substantial direct/indirect economic burden underscore an unmet need. The high number of 1L regimens highlights significant heterogeneity and a lack of consensus related to the management of HR+/HER2- MBC in routine practice.
Collapse
Affiliation(s)
- Ravi K Goyal
- Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
| | - Gebra Cuyun Carter
- Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Saurabh P Nagar
- Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
| | - Emily Nash Smyth
- Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Gregory L Price
- Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Rohan C Parikh
- Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
| | - Yu-Jing Huang
- Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Li Li
- Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Keith L Davis
- Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
| | - James A Kaye
- Epidemiology, RTI Health Solutions, Waltham, MA, USA
| |
Collapse
|
10
|
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 2020; 21:763-775. [DOI: 10.1016/s1470-2045(20)30112-1] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/10/2020] [Accepted: 02/13/2020] [Indexed: 12/15/2022]
|
11
|
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Yang Z, Gianford MC, Price GL, André F. Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p3-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Abemaciclib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)- metastatic breast cancer. In the randomized, 3-arm, phase 2 study monarcHER (NCT02675231) for HR+, HER2+ advanced breast cancer (ABC), abemaciclib in combination with trastuzumab (T) and fulvestrant (F) significantly improved investigator-assessed progression-free survival (whereas abemaciclib + T did not) versus (vs) T + physician’s choice of chemotherapy and demonstrated a tolerable safety profile. Here, patient-reported HRQoL, functioning, and symptoms are reported.
Methods: In monarcHER, 237 postmenopausal (surgical, natural, or chemical ovarian suppression) women with ABC and ≥2 prior HER2+ directed therapies in the advanced setting were randomized 1:1:1 to abemaciclib (150 mg PO Q12H every 21 days) + T (IV infusion on D1 every 21 days) with F (500 mg IM on Cycle 1 D1 and D15 and Cycle 2 D8, then Q4W; Arm A) or without F (Arm B) vs T + physician’s choice of chemotherapy (per label every 21 days; Arm C). Supportive measures to manage diarrhea were permitted. Patient-reported outcomes were measured at baseline and at each cycle using the modified Brief Pain Inventory-short form (mBPI-sf) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The EuroQol 5-Dimension 5 Level (EQ-5D 5L) questionnaire was also collected. Higher scores on EORTC QLQ-C30 functional and health status/QoL scales indicate improvement whereas higher scores on EORTC QLQ-C30 symptom scales and mBPI-sf indicate worsening of symptoms/pain. The EQ-5D 5L index score was calculated from a set of item weights to derive a score of 0-1, with 1 representing the best health status. Treatment arm comparisons of change from baseline (all post-baseline visits) were conducted using a mixed model repeated measure, with .05 considered statistically significant. Clinical meaningfulness was defined as a ≥10-point score change from baseline (on a 0-100 scale) for EORTC QLQ-C30 and a 2-point score change from baseline for mBPI-sf.
Results: Patient-reported outcome compliance rates were ≥90% through Cycle 15; the range for median duration of each treatment component of each arm was 7.5-10.0 cycles. Overall, no statistically significant or clinically meaningful changes from baseline differences were observed between treatment arms for mBPI-sf pain scores or EORTC QLQ-C30 global health score, function scales, or for symptoms of fatigue, dyspnea, appetite loss, or financial difficulties. Least square (LS) mean change from baseline differences showed statistically significant improvements in Arm A vs C for EORTC QLQ-C30 symptoms of pain (-6.81; p=.026) and insomnia (-6.39; p=.041). Worsening for the symptom of nausea/vomiting was statistically significant but not clinically meaningful in Arm A vs C (4.08; p=.043). Diarrhea showed a statistically significant and clinically meaningful worsening in Arm A vs C (19.27; p<.001). A by-cycle analysis showed mean nausea/vomiting and diarrhea symptom scores were generally higher during earlier visits and returned to near-baseline levels after treatment discontinuation. The EQ-5D 5L index score improved in Arm A vs C, with an LS mean change from baseline difference of .05 (p=.033).
Conclusions: Quality of life was maintained for patient-reported pain, global health, functioning, and most symptoms when abemaciclib was added to T + F compared with physician’s choice of chemotherapy in patients with HR+, HER2+ ABC. Gastrointestinal-related symptoms were transient and consistent with the manageable, reversible adverse event profile.
Citation Format: Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, John F. Hilton, Tiffany A Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen RD Johnston, Arlene Chan, Shom Goel, Kristen Catron, Zhengyu Yang, M. Corona Gianford, Gregory L Price, Fabrice André. Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-11-10.
Collapse
Affiliation(s)
| | - Andrew M Wardley
- 2NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust & Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, United Kingdom
| | | | - John F. Hilton
- 4The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
| | | | | | - Seock-Ah Im
- 7Seoul National University College of Medicine, Seoul, Korea, Republic of
| | - Sung-Bae Kim
- 8Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
| | | | - Arlene Chan
- 10Breast Cancer Research Centre - WA and Curtin University, Nedlands, Australia
| | - Shom Goel
- 1Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | | | - Fabrice André
- 12Gustave Roussy, Université Paris Sud, INSERM, Villejuif, France
| |
Collapse
|
12
|
Lim E, Boyle F, Okera M, Loi S, Goksu SS, van Hal G, Hartman DG, Gable JC, Price GL, Hossain A, Gainford MC, Ezquerra MB. Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p5-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Abemaciclib is an orally administered inhibitor of cyclin-dependent kinase (CDK) 4/6, dosed twice daily (BID) on a continuous schedule. Diarrhea is a frequently associated adverse event. It is predictable and manageable with antidiarrheal medication, typically occurs within the first month of therapy, and decreases over the duration of treatment. In the MONARCH 1, 2, and 3 studies, Grade 3 diarrhea was experienced by 9% to 20% of patients (pts) receiving abemaciclib. Study design/Objectives: Study I3Y-MC-JPCP (ClinicalTrials.gov, NCT03703466) was a multicenter, randomized, open-label phase 2 study designed to evaluate the impact of food on the incidence of Grade 3 or prolonged Grade 2 diarrhea in HR+, HER2− metastatic breast cancer (mBC) pts receiving abemaciclib monotherapy 200 mg orally BID during the first 3 cycles of study treatment. Methods: Pts with HR+, HER2− mBC and ECOG performance status ≤1 who had progressed after prior anti-estrogen therapy for mBC and received prior treatment with ≥1 chemotherapy regimen for mBC, but were CDK4/6i naive, were randomly assigned 1:1:1 to receive abemaciclib with a meal, in a modified fasted condition (defined as ≥1 h before or ≥2 h after a meal), or without regard to food. Primary study endpoints were the incidence of ≥Grade 3 diarrhea; incidence of Grade 2 diarrhea lasting >7 days; dose reductions, dose interruptions, and treatment discontinuations due to diarrhea; and use of antidiarrheal agents. Secondary endpoints included overall safety and pharmacokinetic analysis. A pt-held electronic diary was used to record daily information on number of stools, diarrhea, loperamide use, and timing of abemaciclib intake relative to meals. Compliance with diary completion was centrally monitored. Multicenter training and implementation of e-diaries used a variety of paper and electronic resources tailored to end user (research staff, site staff, patient). Physicians had real-time access to data enabling accurate assessment of diarrhea. Results: This study randomized 72 pts in five countries from December 2018 to April 2019; 71 pts (median age 56.0 y) were treated with abemaciclib in one of three study arms: with a meal (Arm 1, n=24), modified fasted condition (Arm 2, n=23) and without regard to food (Arm 3, n=24). Mean compliance for e-diary completion was 95.7% for the overall population. Mean compliance with meal conditions was 99.5% in Arm 1 and 95.2% in Arm 2 (not applicable for Arm 3). In Arms 1, 2 and 3, 83.3%, 78.3% and 91.7% of pts received ≥3 cycles, respectively. Primary endpoints during the first three treatment cycles are summarized (Table).
Table 1Arm 1 (n=24)Arm 2 (n=23)Arm 3 (n=24)Overall (n=71)≥1 Grade 2 diarrhea lasting >7 days, %8.317.420.815.5≥1 Grade 3 diarrhea, %4.2*001.4≥1 Grade 4 diarrhea, %0000≥1 Dose reduction due to diarrhea, %16.78.712.512.7≥1 Dose interruption due to diarrhea, %16.74.38.39.9Treatment discontinued due to diarrhea, %0000Loperamide use, %95.891.395.894.4* Duration of Grade 3 diarrhea was 1 day.
This study was descriptive and not powered to analyze differences between study arms. Overall, the most frequently reported Grade 3/4 treatment-emergent adverse events related to treatment were neutropenia (28.2%), leukopenia (11.3%), thrombocytopenia (7.0%), fatigue (5.6%), nausea (5.6%) and lymphopenia (5.6%). Details on patient-reported diarrhea incidence and management, and PK analyses will be presented at conference. Conclusions: Global compliance with e-diary completion and meal condition was >95%. Diarrhea at high grade occurred at much lower incidence than previously reported (1.4% overall) and was of short duration (1 day). Diarrhea was predominantly low grade and managed with loperamide and dose modifications in all meal cohorts.
Citation Format: Elgene Lim, Frances Boyle, Meena Okera, Sherene Loi, Sema Sezgin Goksu, Gertjan van Hal, Daisy G Hartman, Jonathon Colby Gable, Gregory L Price, Anwar Hossain, M C Gainford, Meritxell Bellet Ezquerra. The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-14-05.
Collapse
Affiliation(s)
- Elgene Lim
- 1Garvan Institute of Medical Research, St. Vincent’s Clinical School, UNSW, Darlinghurst, Australia
| | - Frances Boyle
- 2Patricia Ritchie Centre, Mater Hospital, Sydney, Australia
| | - Meena Okera
- 3Adelaide Cancer Centre, Adelaide, Australia
| | - Sherene Loi
- 4Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | | | | | | | | | | | | | - Meritxell Bellet Ezquerra
- 7Hospital Universitari Vall d'Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
| |
Collapse
|
13
|
Kaufman PA, Toi M, Neven P, Sohn J, Grischke E, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. Oncologist 2020; 25:e243-e251. [PMID: 32043763 PMCID: PMC7011625 DOI: 10.1634/theoncologist.2019-0551] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 09/24/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significantly improved progression-free survival (PFS) versus placebo plus fulvestrant in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC). This study assessed patient-reported pain, global health-related quality of life (HRQoL), functioning, and symptoms. MATERIALS AND METHODS Abemaciclib or placebo (150 p.o. mg twice daily) plus fulvestrant (500 mg, per label) were randomly assigned (2:1). The modified Brief Pain Inventory, Short Form (mBPI-sf); European Organization for Research and Treatment of Cancer (EORTC) QoL Core 30 (QLQ-C30); and Breast Cancer Questionnaire (QLQ-BR23) assessed outcomes. Data were collected at baseline, cycle 2, every two cycles 3-13, thereafter at every three cycles, and 30 days postdiscontinuation. Longitudinal mixed regression and Cox proportional hazards models assessed postbaseline change and time to sustained deterioration (TTSD) by study arm. RESULTS On-treatment HRQoL scores were consistently maintained from baseline and similar between arms. Patients in the abemaciclib arm (n = 446) experienced a 4.9-month delay in pain deterioration (mBPI-sf), compared with the control arm (n = 223), and significantly greater TTSD on the mBPI-sf and analgesic use (hazard ratio, 0.76; 95% CI, 0.59-0.98) and QLQ-C30 pain item (hazard ratio, 0.62; 95% CI, 0.48-0.79). TTSD for functioning and most symptoms significantly favored the abemaciclib arm, including fatigue, nausea and vomiting, and cognitive and social functioning. Only diarrhea significantly favored the control arm (hazard ratio, 1.60; 95% CI, 1.20-2.10). CONCLUSION HRQoL was maintained on abemaciclib plus fulvestrant. Alongside superior PFS and manageable safety profile, results support treatment with abemaciclib plus fulvestrant in a population of patients with endocrine-resistant HR+, HER2-negative ABC. IMPLICATIONS FOR PRACTICE In MONARCH 2, abemaciclib plus fulvestrant demonstrated superior efficacy and a manageable safety profile for patients with in hormone receptor-positive (HR+), HER2-negative (-) advanced breast cancer (ABC). Impact on health-related quality of life (HRQoL) is important to consider, given the palliative nature of ABC treatment. In this study, abemaciclib plus fulvestrant, compared with placebo plus fulvestrant, significantly delayed sustained deterioration of pain and other patient-reported symptoms (including fatigue, nausea, vomiting), and social and cognitive functioning. Combined with demonstrated clinical benefit and tolerability, the stabilization of patient-reported symptoms and HRQoL further supports abemaciclib plus fulvestrant as a desirable treatment option in endocrine resistant, HR+, HER2- ABC.
Collapse
Affiliation(s)
- Peter A. Kaufman
- University of Vermont Cancer Center, University of Vermont Medical CenterBurlingtonVermontUSA
| | - Masakazu Toi
- Department of Surgery, Graduate School of Medicine, Kyoto UniversityKyotoJapan
| | | | | | - Eva‐Maria Grischke
- Department of Women's Health, University Hospital TübingenTübingenGermany
| | | | | | | | | | | | | |
Collapse
|
14
|
Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer. Curr Med Res Opin 2019; 35:1699-1710. [PMID: 31060392 DOI: 10.1080/03007995.2019.1615422] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Background: Endocrine therapy (ET) remains a foundation of systemic therapy for HR+/ HER2- metastatic breast cancer (MBC), although chemotherapy (CT) is used in select patients. In this "real-world" study, we explored treatment patterns, health care resource use (HCRU), costs, adverse events (AEs) and overall survival (OS) in Medicare-enrolled, older patients with HR+/HER2- MBC. Methods: Patients with HR+/HER2- MBC (2007-2011) and aged >66 years were retrospectively analyzed using the SEER-Medicare data. Treatment patterns, HCRU, costs, AEs and OS after MBC diagnosis through end of study period (31 December 2013) were examined using descriptive and multivariable analyses. Results: Among 3622 eligible patients, ET was the most common treatment (77%), followed by CT (50%), radiation (48%) and surgery (19%). The proportion of patients treated with ET monotherapy decreased across therapy lines, from 74% in first line (1 L) to 35% in 4 L. The total number of unique therapy regimens used was 181 in 1 L, 171 in 2 L, 128 in 3 L, and 95 in 4 L. The median OS from MBC diagnosis was 25.3 months (95% CI, 24.0-26.7). In multivariable analyses, receipt of CT and combination CT + ET (versus ET monotherapy) in 1 L, metastatic disease at initial diagnosis, larger tumor size, and presence of visceral and brain metastases at MBC diagnosis significantly predicted receipt of 2 L therapy. Conclusions: ET was the most common first-line treatment for study patients, but its use decreased gradually in the subsequent lines. The heterogeneity in the treatment selection highlights a lack of consensus for the management of HR+/HER2- MBC in routine practice.
Collapse
Affiliation(s)
- Ravi K Goyal
- RTI Health Solutions, Research Triangle Park , Durham , NC , USA
| | | | - Saurabh P Nagar
- RTI Health Solutions, Research Triangle Park , Durham , NC , USA
| | | | | | | | - Li Li
- Eli Lilly and Company , Indianapolis , IN , USA
| | - Keith L Davis
- RTI Health Solutions, Research Triangle Park , Durham , NC , USA
| | | |
Collapse
|
15
|
Vidal GA, Cuyun Carter G, Gilligan A, Saverno K, Zhu YE, Price GL, Deluca A, Nash Smyth EN, Koustenis AG, Huang Y, Schwartzberg LS. Risk stratification based on a prognostic factor index among patients with HR+, HER2- MBC. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e12516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12516 Background: Patient and tumor characteristics, such as tumor grade (TG), site of metastases, hormone receptor status, and endocrine resistance, affect the prognosis for patients (pts) with HR+, HER2- metastatic breast cancer (MBC). This study explored the impact of multiple clinical prognostic factors on pt overall survival (OS) and real-world progression-free survival (rwPFS). Methods: This retrospective study used electronic health record (EHR) data of US pts from a network of community oncology practices maintained in the Vector Oncology Data Warehouse from 1/1/2008 to 4/30/2017. Eligibility included HR+, HER2- MBC diagnosis in 2008 or later and prior systemic therapy for MBC. An index variable was created to assess the effect of multiple clinical prognostic factors collectively, including liver metastases (LM), primary endocrine resistance (PER) (Cardoso F et al. 2018), negative progesterone receptor (PR-) status, and high TG. Pts were grouped based on the number of prognostic factors present at MBC diagnosis: 0, 1, and 2+. Differences in rwPFS and OS from start of first line therapy were evaluated by Kaplan-Meier method and multivariable Cox proportional hazards regression. Results: Eligible pts (n=378) had a mean age of 60.3 years. Among these 57.1% were white, 36.5% were de novo metastatic, 22% had LM, 27.2% had high TG, and 27.1% were PR- at baseline. Among all pts, 170 (45%) had received endocrine therapy as first-line treatment, followed by chemotherapy (28%), CDK4 & 6 inhibitor (17%), or other anti-cancer treatment (9%). After adjustment, rwPFS and OS were significantly (p<.05) shorter in pts with 1 and 2+ clinical prognostic factors compared to pts with none (Table). Conclusions: Among pts with HR+, HER2- MBC, these data demonstrate the heterogeneity in pt survival outcomes depending on the presence and number of prognostic factors. Further research should explore the collective importance of these prognostic factors in treatment decisions. [Table: see text]
Collapse
|
16
|
Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the MONARCH 3 trial, abemaciclib plus an aromatase inhibitor (AI) significantly improved progression free survival and overall response rate with a generally tolerable safety profile compared to placebo plus AI. Here we report patient-reported outcomes (PRO) including health-related quality of life (Qol), functioning, and symptoms.
Methods: MONARCH 3 was a double-blind, randomized phase III study of abemaciclib or placebo plus an AI in 493 post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with no prior systemic therapy in the advanced setting. Two European Organization for Research and Treatment of Cancer (EORTC) questionnaires were included: Quality of Life Questionnaire (QLQ)-Core 30 (C30) and the EORTC QLQ-Breast 23 (BR23) that were assessed at baseline, every 2 cycles through cycle 19, then every 3 cycles until treatment discontinuation, and at short-term follow up. Higher scores on functional and health status/QoL outcomes indicate higher/better levels of functioning or health; conversely higher scores on symptom outcomes indicate higher/worse levels of symptom burden. Between-arm comparisons of change from baseline were conducted using mixed model methods. Statistical significance was set at 0.05 and clinical meaningfulness was set at ≥10 points on a 0-100 scale1.
Results: PRO completion rates were >91% through cycle 19; duration of treatment was longer for abemaciclib plus AI patients (median number of cycles 19 vs.15). Compared to the placebo arm, diarrhea PRO scores in the abemaciclib arm showed a clinically (18.68 points) and statistically significant (p<0.001) increase/worsening. By-cycle analysis showed group mean diarrhea scores returned to near-baseline levels post-therapy. Other symptom PROs showed statistically significant (<0.05) but not clinically meaningful differences; fatigue (4.96; p=0.004), systemic therapy side effects (4.48, p<0.001), appetite loss (4.03; p=0.034), and nausea/vomiting (2.77; p=0.013). These results were consistent with the investigator-reported treatment emergent adverse events (TEAEs). Several non-symptom results were also statistically significant but not clinically meaningful including global health/health status (-4.36; p=0.003), role function (-4.25; p=0.025), social function (-3.41, p=0.047), and body image (-5.11, p=0.009). No statistically significant between-treatment differences were observed for physical, emotional, and cognitive functioning or for symptoms of pain, dyspnea, insomnia, constipation, or financial difficulties.
Conclusions: The addition of abemaciclib to an AI resulted in clinically and statistically significant changes in diarrhea without clinically meaningful differences in other symptom scores. Increased GI-related symptoms were consistent with the manageable, reversible AE profile; the highest symptom burden was reported during early visits. No clinically meaningful differences in global health status or functional scores were observed.
ClinicalTrials.gov: NCT02246621
Reference:
1. Osoba D et al. J Clin Oncol 2002;20(14):3106-13.
Citation Format: Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-16-01.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - S Johnston
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Martin
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - E Tokunaga
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - IH Park
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Huober
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Toi
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GL Price
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Boye
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - L Li
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - T Forrester
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - C Gainford
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Gable
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GC Carter
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A Sood
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A DiLeo
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| |
Collapse
|
17
|
Kaufman PA, Toi M, Neven P, Sohn J, Price GL, Lin Y, Boye M, Li L, Gable J, Cuyun Carter G, Sledge GW. Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.1049] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Peter A. Kaufman
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - Masakazu Toi
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | | | | | | | - Yong Lin
- Eli Lilly and Company, Indianapolis, IN
| | - Mark Boye
- Eli Lilly and Company, Greenwood, IN
| | - Li Li
- Eli Lilly and Company, Indianapolis, IN
| | | | | | | |
Collapse
|
18
|
Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT. A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk Res 2017; 61:89-95. [PMID: 28934680 DOI: 10.1016/j.leukres.2017.08.010] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Revised: 08/17/2017] [Accepted: 08/21/2017] [Indexed: 02/02/2023]
Abstract
Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V617F mutation. The study had a standard 3+3 dose-escalation design to define the maximum-tolerated dose. Primary objectives were to determine safety, tolerability, and recommended oral daily dose of gandotinib for patients with JAK2V617F-positive myelofibrosis, essential thrombocythemia, or polycythemia vera. Secondary objectives included estimating pharmacokinetic parameters and documenting evidence of efficacy by measuring clinical improvement. Thirty-eight patients were enrolled and treated (31 myelofibrosis, 6 polycythemia vera, 1 essential thrombocythemia). The maximum-tolerated dose of gandotinib was 120mg daily, based on dose-limiting toxicities of blood creatinine increase or hyperuricemia at higher doses. Maximum plasma concentration was reached 4h after single and multiple doses, and mean half-life on day 1 was approximately 6h. Most common treatment-emergent adverse events were diarrhea (55.3%) and nausea (42.1%), a majority of which were of grade 1 severity. Best response of clinical improvement was achieved by 29% of myelofibrosis patients. A ≥50% palpable spleen length reduction was observed at any time during therapy in 20/32 evaluable patients. Additionally, ≥50% reduction in the Total Symptom Myeloproliferative Neoplasm Symptom Assessment Form Score was seen in 11/21 (52%) and 6/14 patients (43%) receiving ≥120mg at 12 and 24 weeks respectively. Gandotinib demonstrated an acceptable safety and tolerability profile, and findings at the maximum-tolerated dose of 120mg supported further clinical testing. Clinicaltrials.gov identifier: NCT01134120.
Collapse
Affiliation(s)
- Srdan Verstovsek
- The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
| | - Ruben A Mesa
- Mayo Clinic Cancer Center, 5881 East Mayo Boulevard, Phoenix, AZ 85054, USA.
| | - Mohamed E Salama
- University of Utah School of Medicine, ARUP Reference Laboratories, 500 Chipeta Way, MS 115-G-4, Salt Lake City, UT 84108, USA.
| | - Li Li
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | - Celine Pitou
- Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.
| | - Fabio P Nunes
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | - Gregory L Price
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | - Jennifer L Giles
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | - Deborah N D'Souza
- inVentiv Health Clinical, 225 S. East Street, Indianapolis, IN 46202, USA.
| | - Richard A Walgren
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | - Josef T Prchal
- University of Utah School of Medicine, Division of Hematology, 30 North 1900 East, Salt Lake City, UT 84132, USA.
| |
Collapse
|
19
|
Boye M, Houghton K, Stull DE, Ainsworth C, Price GL. Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.1060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1060 Background: Investigators reporting treatment-emergent adverse events (TEAEs) in the 3rdline or greater abemaciclib MONARCH1 Phase 2 study observed Grade 1-3 diarrhea, fatigue, and abdominal pain in 90, 65, and 39% of the patients (n = 132). Unknown is the extent that diarrhea and overall pain add to fatigue in this setting. Using patient-reported outcome (PRO) measures, we conducted cross-sectional and longitudinal multivariate analyses to estimate these effects. Methods: Data came from a single-arm, open-label study of previously-treated patients with mBC. Throughout the study, the Brief Pain Inventory and the EORTC QLQ-C30 v3 were co-administered. All constructs and items from these two questionnaires –except EORTC Items 25 and 28 (memory and financial difficulties) - were used to estimate the Structural Equation Model (SEM) and the direct and indirect effects of pain and diarrhea on fatigue. Extended pattern mixture modeling (ePMM) – a latent variable modeling method that allows the explicit analysis of missing data and identifies subgroups with differential changes over time – was used to explore these relationships from screening through cycle 8. Results: SEM results showed that at cycle 2 of treatment, pain was a significant predictor of fatigue (b = 0.68; P < 0.001; CI 0.48 – 0.90); diarrhea was not a significant predictor of fatigue (b = 0.06; P = 0.12; CI -0.04 – 0.17). ePMM results across eight 30-day cycles found three fatigue subgroups: no change, improvement, worsening then improvement. Belonging to a similar pain subgroup predicted belonging to the corresponding fatigue subgroup (ref class was no change; improving b = 5.03, P = 0.004; worsening b = 22.01, P < 0.001); the same was not true for diarrhea and fatigue (ref class was no change; improving b = 0.213, P = 0.75; worsening b = 0.04, P = 0.97). Conclusions: These results suggest that for patients undergoing 3rd line or greater mBC treatment, pain is a significant predictor of fatigue early and over the course of the trial. However, diarrhea is not a significant predictor of fatigue. Clinical trial information: NCT02102490.
Collapse
Affiliation(s)
- Mark Boye
- Eli Lilly and Company, Greenwood, IN
| | | | | | | | | |
Collapse
|
20
|
Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang YJ, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Abstract P5-08-18: Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Hormone receptor positive (HR+)/HER2– tumors are the most common subtype among patients with metastatic breast cancer (MBC). Several newer therapeutic options have become available over the last decade, but little is known about the real-world treatment patterns and health care resource use (HCRU) in privately insured women with HR+/HER2– MBC.
Methods
An analysis of Truven MarketScan databases containing medical and drug utilization and productivity data from nearly 350 US payers was conducted. Patients aged 18-64 years with an ICD-9 diagnosis code of breast cancer along with ≥2 claims for secondary malignancy between 2007 and 2013 were selected. HR+/HER2– patients were identified based on receipt of endocrine therapy (ET) and absence of HER2-targeted therapies. Use of cancer-directed treatments following MBC diagnosis was analyzed. Treatment characteristics were examined by line of therapy (LOT). Average monthly all-cause and MBC-related HCRU were descriptively assessed.
Results
A total of 5,563 women with HR+/HER2– MBC (mean [SD] age, 54 [7.8] yrs) met the selection criteria. Overall, 97% of the total sample received ≥1 cancer-directed treatment. The most common treatment was ET (85%), followed by chemotherapy (CT) (70%), radiation (62%), and surgery (11%). Treatment patterns for CT alone and ET alone, including the top regimens by LOT, are presented in Table 1. Among those receiving a second LOT, nearly 44% switched to CT in the second line after having received ET alone in the first line. During the study follow-up, 56% of patients had ≥1 all-cause inpatient admission, 49% had ≥1 all-cause emergency department visit, and 9% had a hospice admission.
Table 1. Treatment patterns by LOT in patients with HR+/HER2- MBCLine 1 Line 2 Line 3 Line 4 n=5,179 (93%)* n=2,900 (52%)* n=1,608 (29%)* n=882 (16%)* n (%) n (%) n (%) n (%)ET Alone3265 (63)ET Alone1468 (51)ET Alone534 (33)ET Alone217 (25)Anastrozole895 (27)Fulvestrant354 (24)Fulvestrant138 (26)Fulvestrant65 (30)Letrozole782 (24)Tamoxifen258 (18)Exemestane89 (17)Exemestane44 (20)Tamoxifen577 (18)Exemestane239 (16)Letrozole82 (15)Tamoxifen25 (12)Fulvestrant428 (13)Anastrozole239 (16)Tamoxifen82 (15)Letrozole20 (9)Exemestane299 (9)Letrozole197 (13)Anastrozole65 (12)Anastrozole14 (6)CT Alone1533 (30)CT Alone1057 (36)CT Alone818 (51)CT Alone505 (57)Paclitaxel413 (27)Capecitabine331 (31)Capecitabine265 (32)Capecitabine140 (28)Capecitabine286 (19)Paclitaxel224 (21)Paclitaxel156 (19)Paclitaxel93 (18)Cyclophosphamide-Doxorubicin → Taxane93 (6)Gemcitabine63 (6)Gemcitabine70 (9)Vinorelbine55 (11)Cyclophosphamide-Docetaxel82 (5)Docetaxel46 (4)Vinorelbine54 (7)Gemcitabine52 (10)Carboplatin-Paclitaxel77 (5)Vinorelbine46 (4)Doxorubicin45 (6)Doxorubicin34 (7)*Out of total 5,563 patients. Only top CT and ET regimens are listed.
Conclusions
A substantial decrease in the use of ET, with simultaneous increase in the use of CT, was observed as patients progressed to subsequent LOTs. Nearly half of those receiving ET alone in the first LOT switched to CT in the second LOT, suggesting a need for more effective non-CT treatments to bridge unmet therapeutic needs in this patient population.
Citation Format: Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-18.
Collapse
Affiliation(s)
- RK Goyal
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GC Carter
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - SN Nagar
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - EN Smyth
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GL Price
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - Y-J Huang
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JL Bromund
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - L Li
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JM Schilder
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - KL Davis
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JA Kaye
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| |
Collapse
|
21
|
Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang YJ, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Abstract P5-08-19: Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Therapeutic advances in metastatic breast cancer (MBC) over the last decade have led to several novel agents for the treatment of patients with hormone receptor positive (HR+)/HER2– MBC. However, current literature has little data on real-world treatment patterns and health care resource use, particularly among elderly women with HR+/HER2– MBC in the United States Medicare population.
Methods
A retrospective analysis of patients aged ≥66 years diagnosed with MBC during 2007 to 2011 was conducted using the SEER-Medicare database. Patients' HR and HER2 status was obtained from the SEER registry data. For patients with no HER2 data available, HER2− disease was determined based on the absence of HER2-targeted therapies within 12 months of diagnosis. Health care utilization and treatment patterns after MBC diagnosis were examined. Use of cancer-directed therapies, including chemotherapy (CT) and endocrine therapy (ET), were descriptively analyzed by line of therapy (LOT).
Results
A total of 3,622 women with HR+/HER2– MBC (mean [SD] age, 77 [7.3] years) were included. Over 90% of women received ≥1 cancer-directed treatment after MBC diagnosis, with ET being the most common (77%), followed by CT (50%), radiation (48%), and surgery (19%). Treatment with ET alone trended downward across LOTs, from 74% in the first LOT to 36% in the fourth LOT, with a corresponding increase in treatment with CT alone from 21% to 46% (Table 1). Among those receiving a second LOT, nearly 26% switched to CT in the second line after having received ET alone in the first line.
Table 1. Pharmaceutical treatment patterns by line of therapy among patients diagnosed with HR+/HER2– MBC (n = 3622)First-Line Second-Line Third-Line Fourth-Line N = 2,981 (82%)* N = 1,449 (40%)* N = 750 (21%)* N = 356 (10%)* n (%) n (%) n (%) n (%)ET Alone2215 (74)ET Alone973 (67)ET Alone381 (51)ET Alone127 (36)Anastrozole893 (40)Fulvestrant282 (29)Fulvestrant99 (26)Fulvestrant38 (30)Letrozole602 (27)Exemestane190 (20)Exemestane76 (20)Tamoxifen27 (21)Tamoxifen253 (11)Anastrozole162 (17)Tamoxifen71 (19)Exemestane25 (20)Fulvestrant243 (11)Tamoxifen152 (16)Anastrozole46 (12)Anastrozole13 (10)Exemestane156 (7)Letrozole107 (11)Letrozole38 (10)Exemestane-FulvestrantN/ACT Alone639 (21)CT Alone336 (23)CT Alone264 (35)CT Alone165 (46)Paclitaxel136 (21)Paclitaxel76 (23)Paclitaxel78 (30)Paclitaxel39 (24)Cyclophosphamide-Docetaxel72 (11)Gemcitabine57 (17)Gemcitabine46 (17)Gemcitabine32 (19)Cyclophosphamide-Doxorubicin → Taxane69 (11)Docetaxel28 (8)Vinorelbine31 (12)Vinorelbine21 (13)Carboplatin-Paclitaxel43 (7)Vinorelbine27 (8)Docetaxel22 (8)Doxorubicin17 (10)Docetaxel39 (6)Doxorubicin21 (6)Doxorubicin21 (8)DocetaxelN/AN/A = not available (in accordance with the SEER-Medicare data use agreement, data for categories with cell size less than 11 are suppressed). *Out of total 3,622 patients. Note: Percentages do not add up to 100% as only the top CT and ET regimens are listed.
Conclusions
ET was the most common first-line treatment for elderly women with HR+/HER2– MBC in this study period. However, as patients progressed from first to fourth LOT, the proportion of patients treated with ET decreased substantially.
Citation Format: Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-19.
Collapse
Affiliation(s)
- RK Goyal
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GC Carter
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - SN Nagar
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - EN Smyth
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GL Price
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - Y-J Huang
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JL Bromund
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - L Li
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JM Schilder
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - KL Davis
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JA Kaye
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| |
Collapse
|
22
|
Fenske DC, Price GL, Nyhuis AW, Hess LM. Abstract P1-07-27: Systematic review of brain metastases in breast cancer in the United States, European Union, and Japan. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-07-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prevalence of brain metastases (BRM) in breast cancer is increasing due to better detection methods and improved patient survival, presenting an unmet need. The exact prevalence is unknown due to a lack of national cancer registries that track BRM cases. Additionally, preceding research presents inconsistent results on survival outcomes, treatment regimens are not well-defined, and there is very limited data on the cost of treating breast cancer BRM. This study was designed to better understand the epidemiology, treatment patterns, cost, and overall survival (OS) of breast cancer patients with BRM in the US, EU, and Japan. Methods: A systematic review following PRISMA guidelines was conducted by searching PubMed, Ovid, and Embase from January 2003 to December 2013. Keywords, MeSH, and Emtree terms were used to define the search strategy. Studies of patients with breast cancer and BRM met eligibility criteria if peer-reviewed, observational, and published in English. Demographic, clinical, and outcomes data were extracted from the publications and entered into Excel. Descriptive statistics were generated with SAS version 9.2. Demographics were summarized, and treatment patterns and median OS were assessed by country. Results: The literature search identified 8,257 articles, of which
245 (n=105,871 breast cancer patients) met eligibility criteria. In these studies, 18,690 breast cancer patients from the US (58.9%), EU (29.5%), and Japan (11.6%) were reported with BRM. Median age of breast cancer patients with BRM was 51.5 years. Patient characteristics are summarized in Table 1. Median OS of breast cancer patients from the time of BRM diagnosis are presented in Table 2. The rate, by country, of radiation therapy among breast cancer patients with BRM ranged from 38.2% to 90.2%, systemic therapy ranged from 5.3% to 46.8%, and surgery was used in 0.8% to 16.2% of studies.
Table 1: Breast Cancer Patient CharacteristicsDemographics of BRM Population(n=18,690)Median Age1 (years)51.5Gender2 (%)Female18,399 (100.0)Male1 (0.0)3Race2 (%)Asian5 (0.4)Black98 (7.1)Hispanic8 (0.6)White1,191 (86.4)Other76 (5.5)Study Enrollment by Country and RegionTotal Studies Reported245Total Breast Cancer Population105,871Total BRM Population (%)18,690EU5,513 (29.5)France3,228 (17.3)Germany812 (4.3)Italy709 (3.8)Spain109 (0.6)UK655 (3.5)Japan2,175 (11.6)US11,002 (58.9)1Reported as the median of medians. 2Not reported in all studies. 3Male breast cancer patient excluded.
Table 2: Reported Median OS1 for Breast Cancer BRM by Treatment Type Systemic TherapyRadiation TherapySurgeryOverallCountryFrance6.906.975.958.17GermanyNR215.0046.0014.00Italy20.4523.6015.5713.50Spain7.755.505.507.75UK5.404.7013.509.50Japan11.408.8010.108.80US10.6011.5011.2011.451Reported in months as the median of medians. 2NR=not reported
Conclusions: Reported median OS and treatment patterns were highly variable across countries. Exposure to risk factors associated with BRM may help explain some of the geographic variability in survival. The lack of published cost data underscores the need to quantify the economic burden of BRM on patients and society.
Citation Format: Fenske DC, Price GL, Nyhuis AW, Hess LM. Systematic review of brain metastases in breast cancer in the United States, European Union, and Japan. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-27.
Collapse
Affiliation(s)
- DC Fenske
- Eli Lilly and Company, Indianapolis, IN
| | - GL Price
- Eli Lilly and Company, Indianapolis, IN
| | - AW Nyhuis
- Eli Lilly and Company, Indianapolis, IN
| | - LM Hess
- Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
23
|
Karve SJ, Price GL, Davis KL, Pohl GM, Smyth EN, Bowman L. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res 2014; 14:555. [PMID: 25392276 PMCID: PMC4242594 DOI: 10.1186/s12913-014-0555-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 10/24/2014] [Indexed: 12/20/2022] Open
Abstract
Background Limited data exist regarding real-world treatment patterns, resource utilization, and costs of extensive-stage small cell lung cancer (esSCLC) among elderly patients in the United States. While abundant data are available on treatment patterns in metastatic non-small cell lung cancer (mNSCLC), to our knowledge no data exist comparing costs and resource use between patients with esSCLC or mNSCLC. Methods We retrospectively analyzed administrative claims data (2000–2008) of patients aged ≥65 years from the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database. Patients were selected on the basis of having newly diagnosed esSCLC (n=5,855) or mNSCLC (n=24,090) during 1/1/2000-12/31/2005, and were required to have received cancer-directed therapy. Survival and other measures were compared between esSCLC and mNSCLC patients using Kaplan-Meier log-rank and univariate chi-square and t-tests. Study measures were followed from first diagnosis date of either esSCLC or mNSCLC until the earlier of death or end of the database. Results Survival between the cohorts did not differ significantly: mean of 10.4 months for esSCLC patients versus 11.1 months for mNSCLC; median survival was 7.4 months versus 5.9 months. A higher percentage of mNSCLC patients (vs. esSCLC) received radiation therapy (75.6% vs. 65.4%; P < 0.001) and surgery (13.6% vs. 7.8%; P < 0.001) during the metastatic disease period. Conversely, a higher percentage of esSCLC patients than mNSCLC patients received chemotherapy (85.5% vs. 60.3%; P < 0.001), red blood-cell transfusion (20.7% vs. 10.9%; P < 0.001), platelet transfusion (5.6% vs. 1.8%; P < 0.001), and growth-factor support (59.0% vs. 39.5%; P < 0.001). esSCLC patients incurred higher lifetime disease-related costs ($44,167 vs. $37,932; P < 0.001) and all-cause costs ($70,549 vs. $67,176; P < 0.001) than mNSCLC patients. Conclusions Lifetime total and disease-related costs per patient were high. Increased use of chemotherapy, supportive care therapies (including growth factors), and disease-related hospitalizations were observed in esSCLC patients as compared with mNSCLC patients. Disease-related and all-cause costs for esSCLC also exceeded those of mNSCLC, except for hospice and skilled nursing services. Survival and per-patient costs for both groups underscore the unmet medical need for more effective therapies in patients with esSCLC or mNSCLC. Electronic supplementary material The online version of this article (doi:10.1186/s12913-014-0555-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sudeep J Karve
- RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, Durham, NC, 27709, USA.
| | - Gregory L Price
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, Indian.
| | - Keith L Davis
- RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, Durham, NC, 27709, USA.
| | - Gerhardt M Pohl
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, Indian.
| | - Emily Nash Smyth
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, Indian.
| | - Lee Bowman
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, Indian.
| |
Collapse
|
24
|
Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014; 9:e90299. [PMID: 24618579 PMCID: PMC3949729 DOI: 10.1371/journal.pone.0090299] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Accepted: 02/01/2014] [Indexed: 12/22/2022] Open
Abstract
Purpose Non-CML myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Reported median overall survival (OS) ranges from a few to several years for MF, a decade or more for ET and PV. The study objective was to compare US survival rates of ET, PV, and MF patients with matched non-MPN/non-cancer controls in a nationally representative database. Patients and Methods Data were taken retrospectively from the Survey, Epidemiology, and End Results (SEER)-Medicare linked database. Medicare enrollees with a new SEER MPN diagnosis between Jan 1, 2001 and Dec 31, 2007 were eligible. First MPN diagnosis was required at or after Medicare enrollment to allow for continuous follow-up. Non-MPN/non-cancer control groups were selected from Medicare separately for each MPN subtype and demographically matched to cases at a ratio of 5∶1. Survival was determined starting from the case diagnosis date using the Kaplan-Meier method. Results A total of 3,364 MPN patients (n = 1,217 ET; 1,625 PV; 522 MF) met the inclusion criteria and were matched to controls. Mean age was 78.4, 76.1, and 77.4 years for ET, PV, and MF, respectively, and percent female was 63, 50, and 41. Median OS was significantly (p<0.05) lower for MPN cases vs. controls (ET: 68 vs. 101 months; PV: 65 vs. 104; MF: 24 vs. 106). Conclusions In the US Medicare population, survival in MF patients was worse than that of patients with ET or PV and significantly worse than matched controls. Survival of patients with ET or PV was substantially inferior to matched controls. These findings have implications for the clinical management of MPN patients and underscore the need for effective therapies in all MPN subtypes.
Collapse
Affiliation(s)
- Gregory L Price
- Eli Lilly and Company, Indianapolis, Indiana, United States of America
| | - Keith L Davis
- RTI Health Solutions, Research Triangle Park, North Carolina, United States of America
| | - Sudeep Karve
- RTI Health Solutions, Research Triangle Park, North Carolina, United States of America
| | - Gerhardt Pohl
- Eli Lilly and Company, Indianapolis, Indiana, United States of America
| | - Richard A Walgren
- Eli Lilly and Company, Indianapolis, Indiana, United States of America
| |
Collapse
|
25
|
Price GL. On the classification of binary shifts of finite commutant index. Proc Natl Acad Sci U S A 1999; 96:14700-5. [PMID: 10611276 PMCID: PMC24711 DOI: 10.1073/pnas.96.26.14700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We provide a complete classification up to conjugacy of the binary shifts of finite commutant index on the hyperfinite II(1), factor. There is a natural correspondence between the conjugacy classes of these shifts and polynomials over GF(2) satisfying a certain duality condition.
Collapse
Affiliation(s)
- G L Price
- Department of Mathematics 9E, United States Naval Academy, Annapolis, MD 21402, USA
| |
Collapse
|
26
|
Abstract
We provide a complete classification up to conjugacy of the binary shifts of commutant index 2 on the hyperfinite II(1) factor. There is a natural correspondence between the conjugacy classes of these shifts and polynomials over GF(2) satisfying a certain duality condition.
Collapse
Affiliation(s)
- G L Price
- Department of Mathematics 9E, United States Naval Academy, Annapolis, MD 21402-5000, USA
| |
Collapse
|
27
|
|
28
|
Price GL. Dentistry's dwndling bank account. Dent Econ 1970; 60:44-6 passim. [PMID: 5266739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
29
|
Price GL. What it really means to retire. Dent Manage 1969; 9:22-7. [PMID: 5254712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|